Cara Therapeutics, Inc. (CARA)
NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
11.97-0.23 (-1.89%)
At close: 4:00PM EDT
11.97 0.00 (0.00%)
After hours: 05:25PM EDT
After hours: 05:25PM EDT
| Previous close | 12.20 |
| Open | 12.26 |
| Bid | 11.93 x 800 |
| Ask | 11.94 x 1300 |
| Day's range | 11.92 - 12.36 |
| 52-week range | 11.58 - 29.65 |
| Volume | 289,475 |
| Avg. volume | 682,185 |
| Market cap | 598.998M |
| Beta (5Y monthly) | 1.31 |
| PE ratio (TTM) | 67.63 |
| EPS (TTM) | 0.18 |
| Earnings date | 10 May 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 27.63 |
- Simply Wall St.
Could The Cara Therapeutics, Inc. (NASDAQ:CARA) Ownership Structure Tell Us Something Useful?
A look at the shareholders of Cara Therapeutics, Inc. ( NASDAQ:CARA ) can tell us which group is most powerful...
- Motley Fool
Is Cara Therapeutics a Buy for Summer 2021?
The future of this troubled clinical-stage biotech rests on a single drug candidate that management hopes will treat an extremely common condition.
- Motley Fool
Is Cara Therapeutics a Buy?
With the clinical trial process in the rearview mirror, a lot of the risks associated with development are in the past, leaving "only" the risks of competing profitably. Such is the situation of Cara Therapeutics (NASDAQ: CARA), which is developing a drug called Korsuva to treat pruritus. You've probably experienced pruritus (at least to a small degree) before, because it's the sensation of itchiness.
© 2021 Verizon Media. All rights reserved.
